Nightingale’s service expands again with a new risk prediction
By Antti Luiro
Summary
- We assess that Nightingale Health's new risk detection tool for high levels of lipoprotein (a) expands its cost-effective blood analysis service, enhancing its healthcare benefits.
- According to the company, the tool targets high-risk individuals, potentially saving up to 80% of costs compared to population-wide screening, by focusing on the 10-20% most likely to have high Lp(a) levels.
- In our view, this development is a standard part of Nightingale's product evolution and supports long-term growth in partnerships and sample volumes, though it does not address immediate growth bottlenecks.
This content is generated by AI. You can give feedback on it in the Inderes forum.
Translation: Original published in Finnish on 9/26/2025 at 8:32 am EEST.
Nightingale Health announced on Thursday the launch of a new risk detection tool that detects a high risk of dangerously high levels of lipoprotein (a), also known as Lp(a). This new feature has been added as part of the company's existing Nightingale Health Check service. This new risk prediction, measured from a single blood sample, further expands the company's cost-effective blood analysis service and, in our view, broadens its benefits in healthcare. We view this as part of the company's standard product development, and this news does not prompt us to adjust our estimates.
New tool for identifying genetic risk factors for cardiovascular disease
According to Nightingale, high Lp(a) levels are a significant genetic risk factor for cardiovascular disease. However, screening the entire population for this condition is expensive. Nightingale's new, patent-pending tool first identifies individuals most likely to have high Lp(a) levels (approximately 10-20% of a given population) and then targets the actual diagnostic test to this high-risk group only. According to the company, this could save up to 80% of the costs compared to measuring entire populations.
The launch of this new feature was not unexpected, as our assessment and the company's communications indicate that its platform has the potential to further expand into identifying new disease risks. This is a normal part of the company's product development, in our view, and the previous risk assessments were published in January. Expanding risk predictions strengthens Nightingale's Health Check service, which we believe will fundamentally support the sale of partnerships and growth in analyzed sample volumes in them in the long term. However, we do not believe the news will directly alleviate the growth bottlenecks caused by time-consuming ramp-ups of healthcare partnerships in the coming years, so it does not warrant any changes to our estimates.
Nightingale Health operates in the medical technology sector. The company specializes in the development of medical technology products. The product portfolio is broad and includes platforms and services within blood analysis that are used for disease prevention purposes. In addition to the main business, service and related ancillary services are also offered. The business is operated globally with the largest presence in Europe.
Read more on company pageKey Estimate Figures19.09
| 2025 | 26e | 27e | |
|---|---|---|---|
| Revenue | 4.7 | 7.9 | 8.8 |
| growth-% | 7.7 % | 67.2 % | 12.1 % |
| EBIT (adj.) | -19.4 | -17.3 | -15.2 |
| EBIT-% (adj.) | -413.7 % | -220.4 % | -172.8 % |
| EPS (adj.) | -0.30 | -0.27 | -0.24 |
| Dividend | 0.00 | 0.00 | 0.00 |
| Dividend % | |||
| P/E (adj.) | neg. | neg. | neg. |
| EV/EBITDA | neg. | neg. | neg. |
Forum discussions
